Clinical trial
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant…
NCT00154388 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00154388 |
|---|---|
| Title | Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases |
| Official title | Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Life Threatening Diseases |
| Intervention type | Drug |
| Interventions | Imatinib mesylate |
| Enrollment | 185 |
| Start date | Feb 1, 2001 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 18, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: